Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Diabetes and HIV: current understanding and future perspectives.

Kalra S, Agrawal N.

Curr Diab Rep. 2013 Jun;13(3):419-27. doi: 10.1007/s11892-013-0369-9. Review.

PMID:
23446780
2.
3.
4.

Metabolic and skeletal complications of HIV infection: the price of success.

Morse CG, Kovacs JA.

JAMA. 2006 Aug 16;296(7):844-54.

PMID:
16905789
5.

Evaluation and management of dyslipidemia in patients with HIV infection.

Green ML.

J Gen Intern Med. 2002 Oct;17(10):797-810. Review.

6.

HIV lipodystrophy and its metabolic consequences: implications for clinical practice.

Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS.

Curr Med Res Opin. 2008 Mar;24(3):609-24. doi: 10.1185/030079908X272742. Review.

PMID:
18208641
7.

Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients.

Tomazic J, Silic A, Karner P, Vidmar L, Maticic M, Poljak M, Ihan A, Janez A.

Wien Klin Wochenschr. 2004 Nov 30;116(21-22):755-9.

PMID:
15628647
9.

Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients.

Stankov MV, Behrens GM.

Curr Pharm Des. 2010 Oct;16(30):3361-71. Review.

PMID:
20687889
10.

Diagnosis and management of common chronic metabolic complications in HIV-infected patients.

Bader MS, Kelly DV.

Postgrad Med. 2008 Nov;120(4):17-27. doi: 10.3810/pgm.2008.11.1930. Review.

PMID:
19020362
11.

Management of metabolic complications and cardiovascular risk in HIV-infected patients.

Blanco F, San Román J, Vispo E, López M, Salto A, Abad V, Soriano V.

AIDS Rev. 2010 Oct-Dec;12(4):231-41. Review.

PMID:
21179187
12.

Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.

Barbaro G.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Aug;5(4):337-43.

PMID:
16101566
13.

Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Anuurad E, Semrad A, Berglund L.

Metab Syndr Relat Disord. 2009 Oct;7(5):401-10. doi: 10.1089/met.2008.0096. Review.

14.

Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection.

Calza L, Masetti G, Piergentili B, Trapani F, Cascavilla A, Manfredi R, Colangeli V, Viale P.

Int J STD AIDS. 2011 Jan;22(1):43-5. doi: 10.1258/ijsa.2010.010256.

PMID:
21364066
15.

Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy.

Samaras K.

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):499-505. doi: 10.1097/QAI.0b013e31819c291b. Review.

PMID:
19223782
16.

Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients.

Florescu D, Kotler DP.

Antivir Ther. 2007;12(2):149-62. Review.

PMID:
17503657
18.

Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.

Shikuma CM, Day LJ, Gerschenson M.

Curr Drug Targets Infect Disord. 2005 Sep;5(3):255-62. Review.

PMID:
16181144
19.

Diabetes in Sub Saharan Africa 1999-2011: epidemiology and public health implications. A systematic review.

Hall V, Thomsen RW, Henriksen O, Lohse N.

BMC Public Health. 2011 Jul 14;11:564. doi: 10.1186/1471-2458-11-564. Review.

20.

Current clinical issues impacting the lives of patients living with HIV/AIDS.

Gallagher DM.

J Assoc Nurses AIDS Care. 2007 Jan-Feb;18(1 Suppl):S11-6.

PMID:
17275717
Items per page

Supplemental Content

Write to the Help Desk